Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 24 for “"FAERS"”.

  1. Analysis of Adverse Events Associated with SGLT2 Inhibitors and Molecular Mechanisms Using FAERS Database and Transcriptome Data

    … Administration Adverse Event Reporting System (FAERS) database to assess adverse events, including myocardial infarction, cardiac failure, tachycardia, acute kidney injury (AKI), renal failure, urinary tract infections, and fungal infections. This analysis was complemented by transcriptomic data …

    usf Repository record for Analysis of Adverse Events Associated with SGLT2 Inhibitors and Molecular Mechanisms Using FAERS Database and Transcriptome Data (opens in a new tab)

  2. COMPARISON OF POST-MARKETING SURVEILLANCE APPROACHES REGARDING INFECTIONS RELATED TO TUMOR NECROSIS FACTOR (TNF) INHIBITORS

    … contrast the FDA Adverse Event Reporting System (FAERS) data and findings from observational studies in post-marketing surveillance through examining TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab and golimumab) related infections, and secondarily, to examine the applicability of …

    unm Repository record for COMPARISON OF POST-MARKETING SURVEILLANCE APPROACHES REGARDING INFECTIONS RELATED TO TUMOR NECROSIS FACTOR (TNF) INHIBITORS (opens in a new tab)

  3. Analysis of the Safety Profile of Cannabis-Derived Products Using the FDA Adverse Event Reporting System Databases

    … Administration Adverse Event Reporting System (FAERS) is a valuable tool for the rapid detection of unexpected emerging safety signals using real-world data. We conducted a descriptive analysis and a disproportionality analysis of CDP-related spontaneous adverse event reports (AERs) queried from …

    ottawa-retro Repository record for Analysis of the Safety Profile of Cannabis-Derived Products Using the FDA Adverse Event Reporting System Databases (opens in a new tab)

  4. Identifying Unexpected Inflammation Resulting from Drug-Drug Interactions

    … from FDA’s Adverse Event Reporting System (FAERS), when combined (in groups of two or more), elicit an inflammatory response and if drug pairs were identified as causing inflammation what were the symptoms? Methods: In this study secondary data was analyzed from the publicly available FAERS …

    central-wash Repository record for Identifying Unexpected Inflammation Resulting from Drug-Drug Interactions (opens in a new tab)

  5. Τεχνολογίες δεδομένων μεγάλης κλίμακας και ανίχνευση ανεπιθύμητων ενεργειών φαρμάκων - φαρμακοεπαγρύπνηση

    … terms we collected and analysed reports from FAERS, for the same period. We also retrieved user posts from Twitter and using an advanced Naïve-Bayes algorithm we detected references of adverse events. Results were analysed using statistics and compared to those of the official adverse event …

    greece Repository record for Τεχνολογίες δεδομένων μεγάλης κλίμακας και ανίχνευση ανεπιθύμητων ενεργειών φαρμάκων - φαρμακοεπαγρύπνηση (opens in a new tab)

  6. Translational high-dimesional drug interaction discovery and validation using health record databases and pharmacokinetics models

    … risk of myopathy were identified in the FAERS and EMR databases by a mixture drug-count response model (MDCM) model. Twenty-eight 3-way and 43 4-way DDI’s increased ratio of area under plasma concentration–time curve (AUCR) >2-fold and had significant myopathy risk in both databases. The …

    iupui Repository record for Translational high-dimesional drug interaction discovery and validation using health record databases and pharmacokinetics models (opens in a new tab)

  7. An Economic and Regulatory Analysis of Gene Therapy Products Authorized by the US Food and Drug Administration and the European Medicines Agency

    … to the FDA Adverse Event Reporting System (FAERS), and assessed the cost-effectiveness analysis of three gene therapies axicabtagene ciloleucel(axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Research Design: For aim 1; data was collected using regulatory …

    chapman Repository record for An Economic and Regulatory Analysis of Gene Therapy Products Authorized by the US Food and Drug Administration and the European Medicines Agency (opens in a new tab)

  8. Incidence of adverse drug events in COVID-19 patients on anticoagulants: a pharmacovigilance study

    … from the FDA’s Adverse Event Reporting System (FAERS) Public Database. Chi-square test of association was performed to determine associations of race, sex and hospitalization rate with the adverse outcome variables. Proportional Reporting Ratios (PRR) and lower 95% confidence intervals (Lower …

    umkc Repository record for Incidence of adverse drug events in COVID-19 patients on anticoagulants: a pharmacovigilance study (opens in a new tab)

  9. Development and Validation of Predictive Risk and Multiple Criteria Decision Analysis Models to Evaluate Cardiovascular Outcomes Among Cancer Patients

    … (MEPS) and FDA Adverse Events Reporting System (FAERS) 2005-2015 files along with literature evidence for our study. We used MEPS database to train our predictive models using ML algorithms such as random forest (RF), gradient boosting and deep learning and compared these to standard regression …

    vcu Repository record for Development and Validation of Predictive Risk and Multiple Criteria Decision Analysis Models to Evaluate Cardiovascular Outcomes Among Cancer Patients (opens in a new tab)

  10. Adverse drug reactions associated with antibiotics : an analysis of the FDA Adverse Event Reporting System

    … limited. The FDA Adverse Event Reporting System (FAERS) provides real-world data on ADRs of antibiotics. Using FAERS, this study 1) discovered new ADR associations for FDA-approved antibiotics, 2) identified an antibiotic-ADR association that was worse for patients on two drugs than on either drug …

    texas Repository record for Adverse drug reactions associated with antibiotics : an analysis of the FDA Adverse Event Reporting System (opens in a new tab)

  11. From Cardiovascular Safety Assessment to Peptide Hemolytic Activity Prediction: Integrative Computational Analyses for Drug Evaluation and Discovery

    … from the FDA Adverse Event Reporting System (FAERS), electronic health records (EHRs) from TriNetX, and transcriptomic analyses were combined to evaluate anesthetic-associated cardiac rhythm adverse drug events. Among propofol, ketamine, dexmedetomidine, and midazolam, dexmedetomidine showed …

    usf Repository record for From Cardiovascular Safety Assessment to Peptide Hemolytic Activity Prediction: Integrative Computational Analyses for Drug Evaluation and Discovery (opens in a new tab)

  12. Using Machine Learning On Diverse Datasets To Predict Drug-Induced Liver Injury

    … (TOX21), and FDA reporting of adverse events (FAERS). Four types of DILI classes were targeted, including two clinically relevant scores and two control classifications, designed by the CAMDA organizers. The L1000 gene expression data had variable drug coverage across cell lines with only 247 …

    nodak Repository record for Using Machine Learning On Diverse Datasets To Predict Drug-Induced Liver Injury (opens in a new tab)

  13. Optimization of Signal-Detection Methods in Novel Databases: a Focus on Direct-Acting Antivirals

    … (FDA) Adverse Event Reporting System (FAERS) is a database containing ADE reports that were submitted to the FDA. The reports need to be investigated, and when working with large databases, signal detection algorithms (SDA) are used to decide which reports are significant. Signal …

    umn Repository record for Optimization of Signal-Detection Methods in Novel Databases: a Focus on Direct-Acting Antivirals (opens in a new tab)

  14. THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE

    … PPR(p)= 1.07 (0.00), EBGM95=0.96 ERAM95=0.89 in FAERS and ROR95=1.48 PPR(p)= 1.34 (0.00) EBGM95=1.22 and ERAM95=0.86 in VigiBase]. GLP-1a and DPP-4 inhibitors (DPP-4i) resulted in better outcomes with a preference for GLP-1a for reducing the risk of major cognitive impairment (dementia) in old …

    milano Repository record for THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE (opens in a new tab)

  15. A pharmacoepidemiological analysis of off-label use of marketed drugs and serious adverse drug reactions

    … Administration Adverse Event Reporting System (FAERS) is presented. Another fifteen cases were identified in the FAERS between 2007 and 2010. Careful monitoring of clinical and laboratory signs of hepatic injury is warranted in patients receiving TZM. In publication 3 characteristics of cases …

    fu-berlin Repository record for A pharmacoepidemiological analysis of off-label use of marketed drugs and serious adverse drug reactions (opens in a new tab)

  16. Analyzing Adverse Events from Publicly Available Web Sources

    … via the FDA Adverse Event Reporting System (FAERS) and privatized reporting systems that house the data from clinical trials. Our focus will be on building a pipeline that demonstrates an open source solution for building a drug’s safety profile from data collection through signal detection. …

    marquette Repository record for Analyzing Adverse Events from Publicly Available Web Sources (opens in a new tab)

  17. Association Between Use of Remdesivir and Bradycardia

    … from the FDA Adverse Event Reporting System (FAERS) database. Patients receiving remdesivir were compared to those receiving Paxlovid, Regen-Cov, and Dexamethasone for COVID-19 treatment to see which group of patients were at a higher risk for bradycardia. This study also sought to determine …

    usf Repository record for Association Between Use of Remdesivir and Bradycardia (opens in a new tab)

  18. Systemic Quinolones and Risk of Adverse Reactions: Integrating Evidence from Clinical and Epidemiological Evidence Streams

    … than 500 hospitals between 2000 and 2016. The FAERS analysis revealed a positive ALF signal with ciprofloxacin and a marginal signal for RD with moxifloxacin. Examination of the evidence from clinical trials revealed only two cases of ALF, one associated with gemifloxacin and one with …

    ottawa-retro Repository record for Systemic Quinolones and Risk of Adverse Reactions: Integrating Evidence from Clinical and Epidemiological Evidence Streams (opens in a new tab)

  19. Contributions to Methods for Adverse Event Identification

    … such as the FDA Adverse Event Reporting System (FAERS) database, provide critical first alerts for emerging medical product safety concerns.In this thesis, we first conduct a comprehensive review of the existing adverse event identification methods, with special emphasis on the postmarketing …

    buffalo Repository record for Contributions to Methods for Adverse Event Identification (opens in a new tab)

Page 1 of 2